Expert Interview
A second discussion on the treatment landscape and the potential of ELREXFIO (elranatamab-bcmm) in patients with multiple myeloma in light of the recent FDA accelerated approval.
Ticker(s): PFEInstitution: Cox Health
- Specializes in hematology, oncology
- Board certified in hematology, oncology, internal medicine
- not an expert or investigator in NK cell immune therapy but familiar with it being another vector that is being looked into as it can be off the shelf immunotherapy.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
